Evidence map›Paper›PMID 22659585›Full record

ArticleEuropean journal of pharmacology2012

Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice.

Sylvia Fitting, Krista L Scoggins, Ruqiang Xu, Seth M Dever, Pamela E Knapp, William L Dewey, Kurt F Hauser

Open access · greenAbstract read
In one paragraph

Article in European journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Effects of acute ΔBrain research · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Expression of Human Immunodeficiency Virus Transactivator of Transcription (HIV-TatJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Independent and Combined Effects of Nicotine or Chronic Tobacco Smoking and HIV on the Brain: A Review of Preclinical and Clinical Studies.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  18. Opioid and neuroHIV Comorbidity - Current and Future Perspectives.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sylvia FittingDepartment of Pharmacolog, Virginia Commonwealth University, Richmond, VA 23298, USA. sfitting@vcu.edu
Krista L Scoggins
Ruqiang Xu
Seth M Dever
Pamela E Knapp
William L Dewey
Kurt F Hauser
Virginia Commonwealth University · USVirginia Commonwealth University Medical Center · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
Opiate drug abuse and CNS vulnerability to HIVP01DA019398 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2005 to 2009
$5.0M
Mechanisms of Opiate Drug-HIV-Induced NeurodegenerationR01DA018633 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2005 to 2021
$4.4M
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 ComorbidityK02DA027374 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2009 to 2018
$1.3M
NIDA NIH HHS K02 DA027374NIDA NIH HHS K02DA027374NIDA NIH HHS P01 DA019398NIDA NIH HHS P01DA019398NIDA NIH HHS R01 DA018633NIDA NIH HHS R01DA018633NIDA NIH HHS R01DA024661NIDA NIH HHS T32 DA007027NIDA NIH HHS T32DA007027
6 · The paper itself

Abstract

Opiate abuse reportedly can exaggerate complications of human immunodeficiency virus type-1 (HIV-1) infection in the central nervous system (CNS), while opiate drugs are often indicated in the treatment of HIV-1-related neuropathic pain. Despite this quandary, few studies have assessed the relationship between the duration or extent of HIV-1 infection and the intrinsic neurobehavioral responsiveness to opioids. To address this problem, doxycycline (DOX)-inducible HIV-Tat(1-86) transgenic mice were used as a model for HIV-1-associated neurocognitive disorders, which permitted the regulation of Tat exposure and duration. The effects of continuous Tat induction on the activity of morphine were examined at weekly intervals using standard behavioral assays for nociception and motor function. In the spinal cord, Tat mRNA levels did not increase until the second and third weeks following induction, which corresponded to a significant loss of morphine antinociception as assessed in the tail-flick test. Alternatively, in the striatum, sustained increases in Tat mRNA expression during the second week of induction coincided with significant decreases in rotarod performance and interactions with morphine. Importantly, the behavioral effects of morphine differed depending on the timing and location of Tat expression, with increases in Tat transcript levels in the spinal cord and striatum corresponding to significant alterations in morphine-dependent nociception and rotarod performance, respectively. Assuming Tat levels contribute to the clinical manifestations of HIV-1, the results suggest that regional differences in viral load and opioid phenotype might influence the nature and degree that opiate responsiveness is altered in HIV-1-infected individuals.

Indexed as

HIV-1AnimalsBehavior, AnimalGene Products, tatHIV InfectionsMaleMiceMice, Inbred C57BLMice, TransgenicMorphinePain MeasurementSpinal CordTreatment OutcomeGene Products, tatMorphine

Identifiers

PMID22659585
PMCPMC3402587
OpenAlexW2088571422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.